Search results for "good"

showing 10 items of 5625 documents

Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale

2010

Schennach-Wolff R, Obermeier M, Seemuller F, Jager M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Objective:  To examine depressive symptoms, their course during treatment, and influence on outcome. Method:  Weekly Calgary Depression Scale for Schizophrenia ratings were performed in 249 inpatients with schizophrenia. Early response was defined as a 20% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia from admission to w…

medicine.medical_specialtyPositive and Negative Syndrome ScaleCase-control studyPoison controlmedicine.disease3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaInternal medicineInjury preventionmedicinemedicine.symptomPsychiatryPsychologySuicidal ideation030217 neurology & neurosurgeryDepression (differential diagnoses)Cohort studyActa Psychiatrica Scandinavica
researchProduct

Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change met…

2015

Significant changes of schizophrenia patients during inpatient treatment were evalutaed and compared to established outcome criteria. The concept of reliable and clinically significant change methods was applied to three hundred and ninety-six patients suffering from a schizophrenia spectrum disorder. First, information on whether or not the change of the patient's condition is sufficient in order to declare that it is beyond a measurement error or random effect (= reliable change) was evaluated and in a second step it was observed if the reliable change was clinically meaningful (= clinically significant change). Different Positive and Negative Syndrome Scale for Schizophrenia (PANSS) thre…

medicine.medical_specialtyPositive and Negative Syndrome ScaleRetrospective cohort studyOutcome assessmentmedicine.diseaseOutcome (game theory)3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaInternal medicinemedicinesense organsAnalysis of varianceYoung adultskin and connective tissue diseasesPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumInternational Journal of Methods in Psychiatric Research
researchProduct

0139 : Extrahospital troponin measurement before admission for a ST segment elevation myocardial infarction

2016

International audience; Background and aimEarly and reliable triage of patients is of major importance to promote rapid and appropriate treatments of patients with ST segment elevation myocardial infarction (STEMI). Extrahospital troponin measurement is used in primary care setting to help the identification of patients with suspected MI. From a regional survey (RICO), we aimed to investigate the frequence and hospital prognosis of STEMI patients with prehospital troponin (PT) measurement.Methods and resultsProspective study on 799 consecutive patients with STEMI included in RICO from March 2013 – 31 may 2015. Among the 799 patients, 38(5%) were identified with PT, from source files and pat…

medicine.medical_specialtyPrimary care030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin (PT) measurementmedicineTroponin measurementST segment030212 general & internal medicineMyocardial infarctionSymptom onsetSTEMI patientsProspective cohort studyIntensive care medicineST segment elevation myocardial infarctionbiologybusiness.industrymedicine.diseaseTroponinTriage3. Good health[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Emergency medicinebiology.protein[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]businessCardiology and Cardiovascular MedicineArchives of Cardiovascular Diseases Supplements
researchProduct

Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity

2005

Summary Background  Chronic urticaria (CU), one of the most common skin disorders, is characterized by spontaneous recurrent bouts of weals and pruritus and associated with severely impaired quality of life (QoL). Objectives  To determine what aspects of life quality are affected and to characterize the factors that impact on QoL in CU patients. Subjects and methods  This interdisciplinary interview/questionnaire-based study included 100 patients admitted to a University Hospital Dermatology Department for the identification of underlying causes of CU; 96 healthy subjects matched for age and sex were used as controls. QoL was assessed using Skindex-29, a validated instrument to measure the …

medicine.medical_specialtyPsychometricsbusiness.industryDermatologyDiseasehumanities3. Good health030207 dermatology & venereal diseases03 medical and health sciencesPsychiatric comorbidity0302 clinical medicineQuality of lifeInternal medicinePhysical therapymedicineAnxietyIn patient030212 general & internal medicinemedicine.symptombusinessChronic urticariaDepression (differential diagnoses)British Journal of Dermatology
researchProduct

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck Module, updated version: Preliminary psychomet…

2015

Background We provided preliminary psychometric data for the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Head and Neck Module, updated version (QLQ-H&N43) from a group of Serbian laryngectomized patients. Methods The study included 170 subjects. The QLQ-H&N43 is a 43-item questionnaire, with 12 multi-item scales and 7 single-item symptom scales. All subjects also completed the Quality of Life Questionnaire-Core 30-questions (QLQ-C30). Results Good internal consistency (Cronbach's α of above 0.7) was found for 5 of the 7 scales. All QLQ-H&N43 scales correlated negatively as predicted with all QLQ-C30 functioning scales. The correlations wi…

medicine.medical_specialtyPsychometricsbusiness.industrymedicine.medical_treatmentDiscriminant validityConstruct validitysocial sciencesPain scalehumanities3. Good healthLaryngectomy03 medical and health sciences0302 clinical medicineOtorhinolaryngologyQuality of lifeCronbach's alpha030220 oncology & carcinogenesisScale (social sciences)otorhinolaryngologic diseasesPhysical therapyMedicine030223 otorhinolaryngologybusinessHead & Neck
researchProduct

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

2017

AbstractTherapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug…

medicine.medical_specialtyPsychopharmacologyGuidelines as Topic030226 pharmacology & pharmacy03 medical and health sciencesNeuropharmacology0302 clinical medicinePharmacotherapyHealth caremedicineHumansPharmacology (medical)PsychiatryIntensive care medicinePsychotropic Drugsmedicine.diagnostic_testbusiness.industryMental DisordersGeneral Medicinemedicine.disease3. Good healthAntiparkinson drugNeuropsychopharmacologySubstance abusePsychiatry and Mental healthTolerabilityTherapeutic drug monitoringDrug Monitoringbusiness030217 neurology & neurosurgeryPharmacogeneticsPharmacopsychiatry
researchProduct

Medications between psychiatric and addictive disorders

2016

International audience; Introduction : Many epidemiological studies have revealed a frequent co-occurrence of psychiatric and substance use disorders. The term used in the literature to refer to this co-occurrence is dual diagnosis. The high prevalence of dual diagnosis has led physicians to observe the effects of medication prescribed to treat psychiatric disorders on the co-occurring substance use disorder and vice versa. The concept of medications between psychiatric and addictive disorders stems from these clinical observations, alongside which, however, it has developed from the observation that both psychiatric and substance use disorders share common neurobiological pathways and trig…

medicine.medical_specialtyPsychotherapistSubstance-Related Disordersmedia_common.quotation_subject[SDV]Life Sciences [q-bio][ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthAddictionModafinilMirtazapine[ SCCO.PSYC ] Cognitive science/Psychology03 medical and health sciences0302 clinical medicineCognitionEpidemiology of child psychiatric disordersmedicineAnimalsHumansDual diagnosisMedical prescriptionPsychiatryClozapineBiological PsychiatryDepression (differential diagnoses)ComputingMilieux_MISCELLANEOUSmedia_commonPharmacologyPsychotropic DrugsDepressionAddictionmedicine.disease3. Good health030227 psychiatrySubstance abuseClinical researchSchizophreniaDiagnosis Dual (Psychiatry)[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health[SCCO.PSYC]Cognitive science/PsychologySchizophreniaDual diagnosisPsychologyPsychiatric disorders030217 neurology & neurosurgery
researchProduct

Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients

2010

International audience; n.a

medicine.medical_specialtyPsychotherapistlcsh:RC435-571[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinelcsh:PsychiatryForensic psychiatry[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthMeeting AbstractmedicinePsychopharmacologyPsychiatryPsychologyNeurocognitive030217 neurology & neurosurgeryGeriatric psychiatryComputingMilieux_MISCELLANEOUS
researchProduct

Unfavorable influence of structured exercise program on total leisure-time physical activity

2012

In randomized controlled trials (RCTs), with customized structured physical exercise activity (SPEA) interventions, the dose of leisure-time physical activity (LTPA) should exceed the LTPA dose of the nonexercising control (C) group. This increase is required to substantiate health improvements achievable by exercise. We aimed to compare the dose of SPEA, LTPA, and total LTPA (SPEA + LTPA) between a randomized Nordic walking (NW) group, a power-type resistance training (RT) group, and a C group during a 12-week exercise intervention in obese middle-aged men (n = 144) with impaired glucose regulation. The dose of physical activity was measured with diaries using metabolic equivalents. No sig…

medicine.medical_specialtyRct designPhysical activityPhysical Therapy Sports Therapy and RehabilitationPhysical exercise030204 cardiovascular system & hematologyMetabolic equivalentlaw.invention03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled trialWeight losslawmedicineOrthopedics and Sports Medicine030212 general & internal medicinebusiness.industryResistance trainingmedicine.diseaseObesity3. Good healthPhysical therapymedicine.symptombusinesshuman activitiesScandinavian Journal of Medicine & Science in Sports
researchProduct

Oral potentially malignant disorders: is malignant transformation predictable and preventable?

2014

Leukoplakia is the most common potentially malignant disorder of the oral mucosa. The prevalence is approximately 1% while the annual malignant transformation ranges from 2% to 3%. At present, there are no reliable clinicopathological or molecular predicting factors of malignant transformation that can be used in an individual patient and such event can not truly be prevented. Furthermore, follow-up programs are of questionable value in this respect. Cessation of smoking habits may result in regression or even disappearance of the leukoplakia and will diminish the risk of cancer development either at the site of the leukoplakia or elsewhere in the mouth or the upper aerodigestive tract. The…

medicine.medical_specialtyReferralOdontologíaReviewMalignant transformationSDG 3 - Good Health and Well-beingstomatognathic systemPredictive Value of TestsOral and maxillofacial pathologymedicineHumansOral mucosaGeneral DentistryLeukoplakiaOral Medicine and Pathologybusiness.industrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgerystomatognathic diseasesmedicine.anatomical_structureCell Transformation NeoplasticOtorhinolaryngologyPredictive value of testsUNESCO::CIENCIAS MÉDICAS/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSurgeryOral lichen planusMouth NeoplasmsCancer developmentLeukoplakia OralbusinessLichen Planus OralMedicina Oral Patologia Oral y Cirurgia Bucal
researchProduct